Q3 2023 Results - Reimagining Medicine
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Novartis pipeline in Phase 1
Oncology
Code
Name
Solid tumors
AAA603 177Lu-NeoB
AAA614 AAA614
AAA817
DFF332 DFF332
HRO761 HRO761
IAG933 IAG933
KFA115 KFA115
MGY825 MGY825
NZV930 NZV930
QEQ278 QEQ278
225AC-PSMA-617
Hematology
DFV890 DFV890
sabatolimab
PIT565
MBG453
PIT565
YTB323
Mechanism
Radioligand therapy target GRPR
Radioligand therapy target FAP
Radioligand therapy target PSMA
HIF2A inhibitor
Werner inhibitor
Novel immunomodulatory Agent
CD73 antagonist
NKG2D/-L pathway modulator
NLRP3 inhibitor
TIM3 antagonist
rapcabtagene autoleucel
CD19 CAR-T
Indication(s)
Multiple solid tumors
Breast cancer
Solid tumors
Metastatic castration-resistant prostate cancer
Renal cell carcinoma
Solid tumors
Mesothelioma
Solid tumors
NSCLC
Solid tumors
Solid tumors
Low risk myelodysplastic syndrome
Low risk myelodysplastic syndrome
B-cell malignancies
Adult ALL
Neuroscience
Code
Name
DFT383 DFT383
NIO752
NIO752
Mechanism
CTNS gene delivery
Tau antisense oligonucleotide
Indication(s)
Cystinosis pre/post kidney transplant
Alzheimer's disease
Progressive supranuclear palsy
Cardiovascular
Code
Name
XXB750 XXB750
Mechanism
NPR1 agonist
34 Investor Relations | Q3 2023 Results
Indication(s)
Heart failure
Conclusions
Appendix
Innovation: Clinical trials
Immunology
References
Abbreviations
INNOVATION
16 lead indications
Code Name
MHV370 MHV370
Mechanism
TLR7, TLR8 Antagonist
Indication(s)
Systemic lupus erythematosus
Others
Name
Mechanism
Code
IB&GH
EDI048 EDI048
EYU688 EYU688
INE963 INE963
CpPI(4)K inhibitor
NS4B inhibitor
Indication(s)
Cryptosporidiosis
Dengue
Malaria, uncomplicated
Lead indication
NOVARTIS | Reimagining MedicineView entire presentation